Why One Small Company — About to Take on an Industry Giant — Won’t Compete on Price

I really tried to make it a whole newsletter without mentioning 340B. I came close, but — alas — I can’t get away. If you want to search Cost Curve

I have a quick rant below about the state of coverage of drug price increases, but I don’t want that to distract you from the drug-price story you should be

The non-Trump news flow remains a trickle. That’s not going to last. Buckle up. It’s going to be an intense 44 days between now and Christmas.  And a shout-out to